Full Press Release Details
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study.
DYN
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
Key Takeaway: Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study